Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
about
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies.Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review.Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.PCSK9 inhibitor valuation: A science-based review of the two recent models.Derivation and validation of a new visceral adiposity index for predicting visceral obesity and cardiometabolic risk in a Korean population
P2860
Q38612448-209298CC-8566-487B-A957-255EB2A5CB72Q46505421-831488FE-3AAE-4D14-A46B-C285941B9CD4Q47392228-46104171-4148-4E35-B7DF-E22B1669A297Q47654133-E72E93AC-F017-4A17-9D8C-6A870AE30029Q48520042-C072948A-AC8A-4F80-90F4-7C5FDD468E03Q48570562-8C74953B-4F8D-43F4-8E46-6C0FE2FE3FADQ52364662-EBB75A15-DEAA-4F92-83BA-307534B7C2DEQ58744167-5A6EBE46-3EEE-46D9-9ABB-178A3D2527E2
P2860
Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Estimated burden of cardiovasc ...... ation in the US payer context.
@en
Estimated burden of cardiovasc ...... ation in the US payer context.
@nl
type
label
Estimated burden of cardiovasc ...... ation in the US payer context.
@en
Estimated burden of cardiovasc ...... ation in the US payer context.
@nl
prefLabel
Estimated burden of cardiovasc ...... ation in the US payer context.
@en
Estimated burden of cardiovasc ...... ation in the US payer context.
@nl
P2093
P2860
P1476
Estimated burden of cardiovasc ...... ation in the US payer context.
@en
P2093
Anne Beaubrun
Armando Lira
Guillermo Villa
Jeroen P Jansen
Mark Danese
Peter P Toth
P2860
P304
P356
10.1080/13696998.2017.1284078
P407
P577
2017-01-18T00:00:00Z